Pre-clinical Studies Update

RNS Number:2700J
Henderson Morley PLC
06 December 2007





                              HENDERSON MORLEY PLC

                                     (AIM)



   Commencement of Pre-clinical studies for PREPS and L-particles as vaccine
                          candidate for herpes simplex



The Board of Henderson Morley plc ("the Company" or "Henderson Morley"), the
drug discovery company, is pleased to announce the start of pre-clinical
toxicity, immunogenicity and dose ranging studies using PREPS and L-particles as
a vaccine candidate for herpes simplex virus ("HSV").



These studies are being carried out by a prestigious US based Contract Research
Organisation and it is anticipated that the studies will be completed by end Q1
2008, with results due by the end Q2 2008.



Commenting Andrew Knight, Executive Chairman, said: "We believe that these
studies will demonstrate a further opportunity for the PREPS and L-particles
vaccine platform in an important disease area.   A successful vaccine against
HSV diseases would have significant market potential."



                                      Ends

ENQUIRIES:



HENDERSON MORLEY PLC                                  Tel: 0121 442 4600
Andrew Knight, Chairman



BISHOPSGATE COMMUNICATIONS LTD                         Tel: 020 7562 3350
Maxine Barnes                                          Mobile: 07860 489571
Nick Rome



BREWIN DOLPHIN SECURITIES LTD                          Tel: 0113 241 0126
Neil Baldwin



Further information on Henderson Morley plc can be accessed through the
Company's website at www.henderson-morley.com


Notes for editors:



There is currently no vaccine licensed for the treatment or prevention of herpes
simplex disease.



Herpes simplex virus infections are the cause of (amongst others);



Genital Herpes

Herpes simplex type 2 (HSV2) causes genital herpes. It is a very common disease
with its incidence growing rapidly, with sero-prevalence*) of HSV2 infection
growing from 16.7% of the US adult population in 1978, to 21.7% in 1991 (NAHNES
study 1997). There are over 45 million Americans chronically infected and at
least 100 million genital outbreaks annually. (UK figures are more difficult to
obtain accurately)



Genital herpes is also the most common ulcerative sexually transmitted disease
in America, and its prevalence has been increasing continually over the last 20
years.



Cold Sores

According to the WHO the current sero-prevalence of HSV 1 globally in adults is
approx 70-80%, leading to at least 400 million cold sores annually.

The sero-prevalence is currently increasing at 3% per year. 42% of sufferers of
HSV1 (cold sores) will have an outbreak in a year (IHMF).89% of sufferers of HSV
2 (genital herpes) will have an outbreak in a year (IHMF).


* Sero-prevalence is the frequency of blood tests demonstrating antibodies to a
particular virus.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

STRKGMGZKKLGNZM

Henderson Mrly. (LSE:HML)
過去株価チャート
から 9 2024 まで 10 2024